Supergen neues Kursziel 18 $ (aktuell 5,21$) und neue Nachrichten!!!! - 500 Beiträge pro Seite

[simon75]

Schaut Euch mal Supergen an, haben ein neues Kurziel und auch aktuell Super-Nachrichten!
Was haltet Ihr davon?


SuperGen Announces Results From Combination Study in CLL Published in the Journal of Clinical Oncology
DUBLIN, Calif., March 14 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that an article entitled, "Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia," appearing in the April issue of the Journal of Clinical Oncology, was published ahead of print on March 6, 2006. Mark A. Weiss and colleagues at the Cleveland Clinic and Memorial Sloan Kettering Cancer Center demonstrated higher response rates and similar or less toxicity using a three-drug combination therapy of pentostatin, cyclophosphamide and rituximab (PCR) for previously treated patients with Chronic Lymphocytic Leukemia (CLL) or other low-grade B-cell neoplasms.

The abstract, 10.1200/JCO.2005.04.3836, was published ahead of print on March 6, 2006, and is available online at http://www.jco.org/cgi/doi/10.1200/JCO.2005.04.3836 . The JCO`s decision to publish ahead of print is made by the editors in conjunction with an article`s authors, and is based on whether the research findings could have a substantial and immediate impact on clinical practice.

Study Purpose

The abstract updates a previously reported study on the use of pentostatin and cyclophosphamide (PC) in 23 patients with relapsed or refractory CLL. The two-drug combination therapy was active and well-tolerated. The study achieved an overall response rate of 74%, including 4 complete responses (17%). In these responders, 41% achieved their best response with PC versus any prior therapy. Encouraged by those results, the researchers undertook the recent study to investigate how the addition of rituximab to the combination therapy would affect the incidence of response, and to characterize the toxicity of the three-drug regimen with PCR in patients with previously treated B-cell CLL or other low-grade B-cell neoplasms.

Methodology

A total of 46 patients with either previously treated CLL (32 patients) or other low-grade B-cell neoplasms (14 patients) were treated. The median age was 62 years, with two prior regimens. Patients received pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2 (PCR). All drugs were administered on the same day (rituximab omitted from cycle 1), and patients received six cycles at 3-week intervals. Filgrastim, sulfamethoxazole/ trimethoprim, and acyclovir were administered prophylactically.

Results

For CLL patients, there were 24 responses (75%), including eight complete responses (25%), one nodular response (NR) and 15 PRs (47%). In fludarabine- refractory patients, 75% responded. Toxicity levels were acceptable, with grade 3/4infections (including fever of unknown origin) in 28% of those treated. The regimen was well-tolerated, with 72% of patients receiving the planned treatment at full dose.

Response Duration and Survival

The addition of rituximab improved response duration, survival and overall toxicity. These studies were done sequentially and are not randomized comparisons. The median survival rate for the 32 CLL PCR patients was 44 months versus 17 months for patients on the two-drug combination therapy (PC). The use of pentostatin in a combination regimen (PCR) appears to be better- tolerated than fludarabine, cyclophosphamide and rituximab (FCR). Comparing this study to results from a similar study using FCR, results included 9% infusion-related toxicity in the PCR group versus 63% with FCR, and infectious complications (including fever of unknown origin) 28% in PCR patients versus 47% in the FCR group.

Conclusion

Combination therapy with pentostatin, cyclophosphamide, and rituximab is an active regimen. The addition of rituximab does not appear to significantly increase overall toxicity, but does appear to confer a survival advantage. As a result of these findings, the researchers are now investigating PCR as initial therapy for CLL patients.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen`s product portfolio includes: Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner.

About Nipent

Nipent(R) (pentostatin for injection) is currently approved as a single- agent treatment for patients with hairy cell leukemia and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication.

[simon75]

SuperGen neues Kursziel
Quelle: Rodman & Renshaw
Datum: 27.02.06

Rating-Update:

Die Analysten von Rodman & Renshaw stufen die Aktie von SuperGen (ISIN US8680591067/ WKN 906575) unverändert mit "market outperform" ein. Das Kursziel werde von 19 auf 18 USD gesenkt.
Analyse-Datum: 27.02.2006

[Larry_1]

Antwort auf Beitrag Nr.: 20.679.013 von simon75 am 14.03.06 16:43:03

Durchstart ist soeben erfolgt
Larry_1

[Larry_1]

Antwort auf Beitrag Nr.: 20.928.527 von Larry_1 am 23.03.06 21:31:41

so, heute scheint ab 15.30 Uhr up zu gehen
Larry_1

[Larry_1]

Antwort auf Beitrag Nr.: 20.936.907 von Larry_1 am 24.03.06 13:46:05

Hmm, da geht einer auf Nummer sicher und verkauft jetzt schon in FRA
Wenn das mal kein Fehler war

[meinBrot]

Ist hier eigentlich noch jemand drin?

mfg meinBrot

[asics01]

<< Back
SuperGen Announces Achievement of $20 Million Dacogen(TM) (decitabine) Injection Milestone
DUBLIN, Calif., May 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that the first commercial shipment of Dacogen(TM) (decitabine) injection was released by MGI PHARMA, INC. to wholesale drug distributors earlier this week. Under the terms of its exclusive worldwide licensing agreement with MGI PHARMA, SuperGen has achieved the $20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com.


Contacts:
SuperGen Noonan Russo
Timothy L. Enns Sharon Weinstein
S.V.P., Corporate Communications Director of Investor Relations
& Business Development
Tel: [phone] x111 Tel: [phone]
E-mail: [e-mail] E-mail: [e-mail]

SOURCE SuperGen, Inc.
05/26/2006

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & Business
Development of SuperGen, [phone] ext. 111, [e-mail]; or
Sharon Weinstein, Director of Investor Relations of Noonan Russo,
[phone], [e-mail]
Web site: http://www.supergen.com
(SUPG)

[Larry_1]

02.06.2006 14:04
SuperGen Receives U.S. Patent For Nipent(R)(Pentostatin For Injection)

DUBLIN, Calif., June 2 /PRNewswire-FirstCall/ -- SuperGen, (Nachrichten) Inc. today announced the issuance of U.S. Patent No. 7,037,900 B2 entitled, "Composition and Method for Treating Graft-versus-Host Disease." The patent contains 39 claims relating to the composition and methods for treating graft-versus-host disease (GvHD) and, more specifically, to the administration of inhibitors of adenosine deaminase (ADA). In particular, novel formulations of ADA inhibitors such as pentostatin are utilized for suppressing T-lymphocyte mediated immune responses while minimizing systemic toxicity of the drug.

"This is SuperGen's first patent relating to the use of Nipent(R) in graft-versus-host disease, and it enhances the potential value of our franchise beyond the current approved indication of Hairy Cell Leukemia," said Edward L. Jacobs, Chief Operating Officer. "Nipent(R) is being studied in a large number of trials in a variety of clinical settings. This patent supports the ongoing efforts of clinical investigators to explore further Nipent's utility in GvHD."

About Nipent

Nipent(R) (pentostatin for injection) is currently approved as a single-agent treatment for patients with Hairy Cell Leukemia, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication.

About Graft -versus -Host Disease (GvHD)

GvHD is a condition that results when the immune cells of a transplant (usually of bone marrow) from a donor attack the tissues of the person receiving the transplant.


Irgendwann kommt auch die SUPG wieder auf die "Beine".
Diese Meldung hat auf jeden Fall mal etwas Auftrieb gegeben.

Spannender ist es da schon bei eher bei ENCYSIVE PHARMACEUTICALS
Larry_1

[Larry_1]

muß natürlich heißen:
Spannender ist es da schon bei ENCYSIVE PHARMACEUTICALS

[asics01]

SuperGen Completes Contract to Transition Wyeth Distribution of Nipent(R), Outside of the U.S.
DUBLIN, Calif., June 6 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) today announced that a contract has been executed to terminate the distribution of Nipent(R) (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The Company paid Wyeth a $2.1 million dollar early termination fee, making it effective June 1, 2006. SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen's subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom.

EuroGen will have a commercial presence at the upcoming European Hematology Association (EHA) meeting in Amsterdam, The Netherlands. Additionally Nipent will be discussed within a symposium on June 15 at EHA entitled "M.D. Anderson Cancer Center Approach to Patients with Hematological Malignancies," chaired by Michael J. Keating, M.D.

About Nipent

Nipent(R) (pentostatin for injection) is currently approved as a single- agent treatment for patients with Hairy Cell Leukemia in the United States and selective counties within Europe, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication in any territory.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen Noonan Russo
Timothy L. Enns Sharon Weinstein
S.V.P., Corporate Communications Director of Investor Relations
& Business Development
Tel: [phone] x111 Tel: [phone]
E-mail: [e-mail] E-mail: [e-mail]


SOURCE SuperGen, Inc.
/Web site: http://www.supergen.com
(SUPG)

[asics01]

Mayne Acquires SuperGen's North American Oncology Products
DUBLIN, Calif. and MELBOURNE, Australia, June 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Mayne Pharma Limited (ASX: MYP) and SuperGen, Inc. (Nasdaq: SUPG) announced today that they have signed a definitive agreement for Mayne Pharma to acquire the North American rights to Nipent(R) (pentostatin for injection) and SurfaceSafe(TM) from SuperGen, Inc. for a total maximum consideration of US$34 million inclusive of approximately US$14 million upfront at signing. The remaining payments are contingent on key events and product performance. The transaction is subject to customary closing conditions.

Nipent(R) is a treatment approved for patients with hairy cell leukemia and SurfaceSafe(TM) is a two step, towelette system to decontaminate surfaces where chemotherapy is mixed or administered.

Commenting on the acquisition today, Mayne Pharma's Chief Executive Officer and Managing Director Dr. Thierry Soursac said, "A key element of Mayne Pharma's new strategy, presented last month, is to acquire niche marketed or close-to-market proprietary products that strengthen our oncology focus and leverage our development, manufacturing and marketing capabilities. The addition of Nipent(R), therefore, fits our strategy perfectly, building on our core oncology capability, particularly in the important US market. In addition, since Nipent(R) is a proprietary product, this transaction will raise Mayne Pharma's profile with key customers and opinion leaders, further strengthening our position."

Dr. James S. Manuso, President and Chief Executive Officer of SuperGen, commented, "We are encouraged by Mayne Pharma's commitment to the oncology market and the continuing development of the Nipent(R) franchise. The added financial strength this transaction affords will further enable SuperGen to rapidly develop and commercialize our targeted therapeutics."

Under the terms of the proposed transaction, Mayne Pharma will acquire all product rights, patents, registrations, trademarks, inventories and relevant supplier and customer contracts related to Nipent(R) in North America and SurfaceSafe(TM). The parties are working towards executing additional agreements for the acquisition of mitomycin, a cytotoxic cancer therapeutic, for the US market as well as any SuperGen rights to these products outside of the United States.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, SurfaceSafe(R) cleaner, and a number of preclinical products being developed as inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

About Mayne Pharma

Mayne Pharma Limited is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development-stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US 500 million in its financial year ended 30 June 2005 and is listed on the Australian Stock Exchange under the symbol 'MYP'. For more information about Mayne Pharma, please visit http://www.maynepharma.com.

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. These forward-looking statements include statements regarding the ability of the proposed transaction to strengthen SuperGen's financial position and enable SuperGen to commercialize its other products. Such statements are just predictions and involve risks or uncertainties such that actual results and performance may differ materially. Factors that might cause such a difference include (1) the failure of the parties to consummate the proposed transaction, (2) failure by Mayne to achieve the revenue milestones, resulting in SuperGen's failure to earn the deferred payments under the agreement. These and other risks are detailed from time to time in SuperGen's periodic filings with the Securities and Exchange Commission, including the report on Form 10-K for the fiscal year ended December 31, 2005 and on Form 10-Q for the quarter ended March 31, 2006. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Nipent(R) is a registered trademark of SuperGen, Inc.

CONTACT:
For further information about Mayne Pharma, please contact:
Jihad Manai Andrew Rowe
Corporate Communications and Public Affairs Investor Relations
Mayne Pharma Mayne Pharma
[phone] [phone]
[e-mail] [e-mail]

For further information about SuperGen, please contact:
Timothy L. Enns Sharon Weinstein
SuperGen, Inc. Noonan Russo
Tel: [phone] x111 Tel: [phone]
E-mail: [e-mail] E-mail: [e-mail]


SOURCE SuperGen, Inc.


Jihad Manai,
Corporate Communications and Public Affairs,
[phone],
[e-mail],
or Andrew Rowe, Investor Relations,
[phone],
[e-mail],
both of Mayne Pharma;
or Timothy L. Enns of SuperGen,
Inc.,
[phone] x111,
[e-mail]; or Sharon Weinstein of Noonan Russo,
[phone],
[e-mail], both for SuperGen, Inc.

[asics01]

SuperGen Announces Attainment of Milestone from the MGI PHARMA / Cilag GmbH, a Johnson & Johnson Company, Licensing for Dacogen(TM) (Decitabine) for Injection
- Ex-North America Development & Commercialization Agreement -
DUBLIN, Calif., July 6 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), announced the achievement of a milestone as a result of the licensing of Dacogen(TM) (decitabine) for Injection by MGI PHARMA to Cilag GmbH, a Johnson & Johnson (JNJ) company, granting exclusive development and commercialization rights in all territories outside North America. Dacogen is a treatment for patients with myelodysplastic syndromes (MDS) which occur when there is a defect in the blood-forming stem cells, resulting in too few and poorly functioning blood cells. SuperGen will receive 50% of the $10 million upfront payment and as a result of both the original agreement with MGI PHARMA and this sublicense with Cilag GmbH up to $23.75 million in future milestone payments as they are achieved for Dacogen globally. Additionally, SuperGen will receive the 20% to 30% royalty on all sales worldwide.

"Janssen-Cilag companies have established a record of success in the field of hematology," said Dr. James Manuso, President and CEO of SuperGen. "The combination of MGI PHARMA and Janssen-Cilag as global developers and marketers of Dacogen should accelerate the availability of this product to patients worldwide."

MGI PHARMA and the Janssen-Cilag companies will jointly implement a strategic plan for the global clinical development of Dacogen. Under the terms of this agreement, MGI PHARMA will retain all commercialization rights to Dacogen in North America. Janssen-Cilag companies will be responsible for conducting regulatory and commercial activities related to Dacogen in all territories outside North America, while MGI PHARMA retains all responsibility for all activities in the United States, Canada and Mexico.

About Dacogen(TM) (decitabine) For Injection

Dacogen(TM) (decitabine) for Injection was approved by the U.S. Food and Drug Administration on May 2 and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups. Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards. The most commonly occurring adverse reactions with Dacogen include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Please visit http://www.mgipharma.com for full prescribing information.

MGI PHARMA is currently conducting a phase 3 pivotal trial to evaluate Dacogen in patients with acute myeloid leukemia, or AML. Additional phase 2 studies are also underway to evaluate alternative dosing regimens for Dacogen in patients with MDS and in patients with AML and chronic myelogenous leukemia, or CML. A phase 3 EORTC-sponsored study of Dacogen in patients with MDS is ongoing in Europe.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of Dacogen to receive marketing authorization from regulatory authorities and to ultimately compete successfully with other therapies, and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q or 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts:
SuperGen
Timothy L. Enns
S.V.P., Corporate Communications & Business Development
Tel: [phone] x111
E-mail: [e-mail]

Noonan Russo
Sharon Weinstein
Director of Investor Relations
Tel: [phone]
E-mail: [e-mail]


SOURCE SuperGen, Inc.
CONTACT:
Timothy L. Enns,
S.V.P.,
Corporate Communications & Business Development of SuperGen,
[phone] x111,
or [e-mail];

or Sharon Weinstein,
Director of Investor Relations,
[phone],
or, [e-mail], of Noonan Russo for SuperGen, Inc.
Web site: http://www.supergen.com
http://www.mgipharma.com
(SUPG)

[Taketwo]

Hallo,

ich bin sehr entaeuscht von Supergen! Ich haette nie geglaubt, das die Aktie so faellt! Gibt es dafuer einen sinnvolle Erklaerung? Bitte um Info, falls es welche gibt!

[asics01]

ich denke mal das die zahlen morgen gut sein werden,und dann gehts ab.

[Taketwo]

Antwort auf Beitrag Nr.: 23.071.313 von asics01 am 26.07.06 21:06:56

Hmm,... die Zahlen waren wohl nicht so gut! Heute ueber 10 Prozent verloren! Was laeuft denn da gerade!

[Taketwo]

52-Wochen-Tief erreicht! Da ist wohl ein Loch im Booooooooooooooden!!!
Aber scheinbar bin ja nur ich arme Sau hier investiert!!!
Habe ich keine Leidensgefaehrten????

[asics01]

doch ich bin bei dir.ich kann mir das auch nicht erklären keine schlechte nachrichten aber immer runter.wird vielleicht künstlich gedrückt,will hier jemand günstig kaufen???ich werde morgen eventuell noch mal nachlegen.

[asics01]

wer kauft denn da seit 3 tagen immer die gleichen stückzahlen wie ich ein

[asics01]

Mayne Pharma's Purchase of SuperGen's North American Oncology Products Completes
DUBLIN, Calif. and MELBOURNE, Australia, Aug. 23 /PRNewswire/ -- Mayne Pharma Limited (ASX: MYP) and SuperGen, Inc. (Nasdaq: SUPG) today announce that the proposed acquisition of the North American rights to SuperGen's Nipent(R) (pentostatin for injection) and SurfaceSafe(TM), as communicated on 22 June 2006, has completed.

Mayne Pharma will pay a total maximum consideration of US$34 million inclusive of approximately US$14 million at completion. Remaining payments are contingent on key events and product performance.

For further information about Mayne Pharma, please contact:

Investor Contact Media Contact
Andrew Rowe Teresa La Thangue
Vice President Investor Relations Media Relations Manager
Ph: [phone] Ph: + 44 (0) 20 7420 8479
Mobile: [phone] Mobile: [phone]
or
Sue Cato
Ph: [phone]
Mobile: [phone]

For further information about SuperGen, please contact:

Timothy L Enns Sharon Weinstein
SuperGen, Inc. Noonan Russo
Tel: [phone] x 111 Tel: [phone]
[e-mail] [e-mail]

Notes to editors:

About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, SurfaceSafe(R) cleaner, and a number of preclinical products being developed as inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com/" target="_blank" rel="nofollow ugc noopener">http://www.supergen.com/ .

About Mayne Pharma

Mayne Pharma Limited is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US 500 million in its financial year ended 30 June 2005 and is listed on the Australian Stock Exchange under the symbol 'MYP'. For more information about Mayne Pharma, please visit http://www.maynepharma.com .

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. These forward-looking statements include statements regarding the ability of the proposed transaction to strengthen SuperGen's financial position and enable SuperGen to commercialize its other products. Such statements are just predictions and involve risks or uncertainties such that actual results and performance may differ materially. Factors that might cause such a difference include (1) the failure of the parties to consummate the proposed transaction, (2) failure by Mayne to achieve the revenue milestones, resulting in SuperGen's failure to earn the deferred payments under the agreement. These and other risks are detailed from time to time in SuperGen's periodic filings with the Securities and Exchange Commission, including the report on Form 10-K for the fiscal year ended December 31, 2005 and on Form 10-Q for the quarter ended June 30, 2006. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Nipent(R) is a registered trademark of SuperGen, Inc.


SOURCE SuperGen, Inc.
CONTACT: Investors: Andrew Rowe, Vice President Investor Relations, [phone], Mobile: [phone], or Media: Teresa La Thangue, Media Relations Manager, [phone], Mobile: [phone], or Sue Cato, [phone], Mobile: [phone], all for Mayne Pharma Limited; Timothy L Enns, of SuperGen, Inc., [phone] x 111, [e-mail]; Sharon Weinstein of Noonan Russo, [phone], [e-mail], for SuperGen, Inc.
Web site: http://www.supergen.com
http://www.maynepharma.com
(SUPG)

na also geht doch geduld war heir gefragt

[asics01]

ziemlich ruhig hier, keiner mehr investiert???keine meinungen???

[Taketwo]

Antwort auf Beitrag Nr.: 24.454.769 von asics01 am 06.10.06 21:48:51

Hallo asics01,

ich bin, zum Glück, noch investiert!
Aber es scheint irgendwas zu geben, was man in Amerika schon weiss, aber hier bei uns noch nicht! Anders kann ich mir den ständigen Anstieg, der nur ein Nachziehen der US-Kurse in Deutschland darstellt, da hier fast kein Umsatz stattfindet, nicht erklären! Auf der Homepage von Supergen konnte ich keine neuen News finden, aber irgendetwas ist im Busch!!!

[asics01]

Antwort auf Beitrag Nr.: 24.533.580 von Taketwo am 10.10.06 13:20:12

hallo taketwo
das interesse an supg ist in d noch nie groß gewesen,was kann kommen ???gute forschungsergebnisse mit orathecin??aber zeit wird es nun mal auch das sich vom kurs her was bewegt,denn die erfolge der letzten monate (zulassungen,partnerschaften ...)müssen ja auch mal honoriert werden.da hats noch genug luft nach oben.
asics

[Taketwo]

Antwort auf Beitrag Nr.: 24.538.811 von asics01 am 10.10.06 17:01:22

Wir haben doch gerade im Moment einen schönen Aufwärtstrend. Und der ist auch heute ungebrochen! Das ganze wird ja in Deutschland nur durch den US-Kurs bestimmt. wie Du schon sagst: Interesse und Umsatz in D fast Null!
Aber in US werden immer wieder grössere Pakete gekauft. Es würde mich interessieren, ob es irgendeine News gibt, die wir hier noch nicht kennen! Oder ob es die Reaktion auf die alten News sind.
Vielleicht gibt es was Neues zu dem neuen Krebsmittel (Drago...???)
Möglicherweise sind die Ergebnisse der Tests positiv. Weisst Du, ob das Mittel in Amerika schopn verkauft wird? Wenn ja, könnten positive Umsatzzahlen hinter der Kurssteigerung stecken!

[asics01]

der aufwärtstrend ist da ,wird auch zeit denn supg wurde doch die letzten jahre nur gezockt und unten gehalten.die haben ja jetzt ihr dacogen und nippent auf den markt gebracht und deren orathecin in phase3 ist auch nicht ohne.ich bleibe dabei wenns gut läuft sehen wir bald die 10$.aber wie du gesagt hast die umsätze der letzten tage lässt eventuell vermuten das da was ansteht, was immer auch das ist.

[Taketwo]

Wir naehern uns mit grossen Schritten dem 52-Wochen-Hoch!!! Und keiner in Deutschland merkt es! Ich denke, dass ist noch nicht das Ende der Fahnenstange! Der Kurs an der NASDAQ steigt auch weiter! Da ist sicher was im Busch!!! Da wird es demnaechst eine sehr gute News geben! Und einige Trader in U.S. kennen die scheinbar schon!
Jetzt fahren wir endlich Gewinne ein! Hat sich mein Long doch bewaehrt!

[asics01]

supergen wird gewaltig unterschätzt,die haben noch gewaltiges potential nach oben.die zahlen werden super ausfallen irgendwas kommt, hoffen wir auf top news.

[asics01]

SuperGen to Present at BIO InvestorForum
DUBLIN, Calif., Oct. 11, 2006 - SuperGen Inc. (Nasdaq: SUPG) today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, will present a corporate overview and highlight SuperGen's recent developments at the 2006 BIO InvestorForum, at 2 p.m. PDT, on Oct. 18, 2006, at the Palace Hotel in San Francisco.

A live Webcast of Dr. Manuso's presentation will be available on the Investor Relations section of the Company's website at www.supergen.com. The Webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

.


Contacts:
SuperGen Noonan Russo
Timothy L. Enns Sharon Weinstein,
S.V.P., Corporate Communications [phone] (Investors)
& Business Development [e-mail]
[phone] x111
[e-mail] Tracey Milani, [phone] (Media)
[e-mail]

[Taketwo]

Quelle: www.supergen.com (Homepage Supergen)

SuperGen Announces 2006 Third Quarter Financial Results Conference Call to be Webcast Nov. 1, 2006
DUBLIN, Calif., Oct. 24 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG) today announced that the company will issue its third quarter financial results at 4:00 p.m. EST on Wednesday, Nov. 1, 2006. SuperGen will host a conference call with the financial community to discuss operational and financial results for the three months ended Sept. 30, 2006 and any revised outlook for the future. A live Webcast of this conference call will begin at 4:30 p.m. EST on Wednesday, Nov. 1, 2006.

This call is being Webcast by CCBN and can be accessed in the Investor Relations section of SuperGen's Web site at www.supergen.com. A replay will be available in the same location for 90 days following the call.

The Webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).

Ich denke, nach dieser Veranstaltung werden wir mehr wissen, bzw. bin ich mir sicher, dass in Amerika schon einige mehr wissen! Meiner Meinung nach, sind die Ergebnisse besser als vermutet! Dann bekommt die Aktie nochmal einen Schub! Ich denke, wir sehen die 7 $ noch dieses Jahr!

[asics01]

es kommt etwas die umsätze bei supg heute und die letzten tage lassen das erahnen,ich glaube auch das wir die 7$ bald hinter uns haben.supg ist eine perle und keinen interessiert es.

[asics01]

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB(TM) Process in Drug Discovery and Design
PRAGUE, Czech Republic, Nov. 9 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG) today announced the presentation of four posters describing preclinical data on MP-529, one of the company's selected lead compounds, and several discovery programs during the scientific sessions at the 18th EORTC- NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

The research presented by SuperGen scientists during Thursday's sessions included data pertaining to MP-529, a potent and selective Aurora-A kinase inhibitor (Poster 341). Three posters also demonstrated the use of SuperGen's proprietary CLIMB technology and drug discovery process to facilitate lead development and design of several novel small molecule inhibitors, including Axl kinase (Poster 413); Pim-1 kinase (Poster 414); and Polo-like kinase-1 (Poster 415).

"We are extremely pleased that SuperGen's drug discovery and development capabilities are well-represented at this internationally recognized scientific forum that showcases the latest breakthrough discoveries and early clinical data on advances in the treatment of cancer," said Dr. James S. Manuso, SuperGen's Chairman, President and Chief Executive Officer. "We have a total of six posters and a podium presentation at EORTC this year. The research we presented today highlights the rapid progress we have made on our late-stage preclinical compounds and also validates CLIMB as a rapid and powerful process for the identification of potent small molecule inhibitors."

Poster No. 341

The discovery of MP529, a potent and selective aurora kinase inhibitor, using CLIMB

SuperGen developed a series of lead compounds for use in anticancer therapy using rational-based drug design. Extensive in silico screening reduced the number of compounds submitted to physical assays to less than 100, saving significant time and resources over standard drug discovery practices. MP-529 series compounds such as SGI-498, SGI-503, SGI-1097 and SGI-1215 exhibit potent inhibitory activity against the Aurora-A enzyme with IC50 concentrations all in the nanomolar range. All four leads have greater than 10-fold selectivity for the Aurora-A enzyme over the Aurora-B enzyme which distinguishes them from other reported Aurora kinase inhibitors.

Poster No. 413

Discovery and characterization of a series of Axl kinase inhibitors using the CLIMB process

Using CLIMB, a model of Axl kinase was created and used to screen a large virtual library of chemical structures from which five chemical lead scaffolds were selected. Inhibitor SGI-AXL-277, a pyrrolopyrimidine, has demonstrated low micromolar activity against the Axl enzyme and in cell proliferation assays and lead optimization from this initial lead is ongoing leading toward the selection of a clinical candidate.

Poster No. 414

Discovery and characterization of a small molecule inhibitor for Pim-1 kinase

Using CLIMB, researchers identified imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives as scaffolds for inhibitors of Pim kinases. The primary screen of compounds selected from the in silico virtual screens identified inhibitors with good activity against the Pim enzyme at low micromolar activity. Optimization of compounds based on SAR led to next- generation compounds that retained the potent activity against the Pim-1 enzyme, but dramatically increased the cell-based activity of these compounds. Lead candidate properties were optimized using CLIMB and animal testing has initiated.

Poster No. 415

Discovery and characterization of novel small molecule inhibitors of polo- like kinase-1 using a computational development process

The CLIMB process of model development and testing reduced a very large selection of potential polo-like kinase-1 inhibitors to an easily manageable selection of hits, all with measurable activity against the target. A polo- like kinase-1 homology model was generated based on Aurora-A kinase and Protein Kinase-B. Using CLIMB, researchers generated three scaffold leads based on the 6_3_8, 6_23_118, and pyrimidine backbones were shown to have good inhibitory activity against the Plk-1 enzyme. These compounds were also shown to inhibit Panc1 and HT29 cancer cell proliferation and increase the rate of apoptosis in MiaPaCa-2 cancer cells in a dose-dependent manner.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding SuperGen's estimate of its potential tax liability. Important factors that could cause the potential tax liability to be higher or lower include, but are not limited to, the final determination of the potential liability which is currently being assessed. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.


Contacts:
SuperGen
Timothy L. Enns
S.V.P., Corporate Communications & Business Development
[phone] x111
[e-mail]


Noonan Russo
Sharon Weinstein, [phone] (Investors)
[e-mail]
Tracey Milani, [phone] (Media)
[e-mail]


SOURCE SuperGen Inc. 11/09/2006


Web site: http://www.supergen.com
(SUPG)


2222 11/09/2006 09:16 EST http://www.prnewswire.com


"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding SuperGen's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.


Copyright © Supergen



Investors > News Releases

[asics01]

SuperGen Reports 2006 Third Quarter Financial Results
$5 Million Milestone Earned From Dacogen Sub-Licensing Agreement

DUBLIN, Calif., Nov. 9 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG) today reported financial results for the three and nine months ended September 30, 2006.

Total revenues for the 2006 third quarter were $8.3 million compared with $8.6 million for the same prior year period. Total revenues for the 2006 third quarter reflects a $5.0 million milestone payment included in development and license revenue and $1.0 million in royalty revenue pursuant to the license agreement entered into with MGI PHARMA during 2004, which granted MGI exclusive rights to the development, manufacture, commercialization and distribution of Dacogen(TM) (decitabine) for Injection. Net product revenue for the 2006 third quarter included Nipent(R) (pentostatin for injection) sales of approximately $1.9 million, compared with $5.1 million for the same prior year period. The decrease in net product revenue during the 2006 third quarter is primarily due to the sale of the Company's North American rights for Nipent and Surface Safe(R) to Mayne Pharma that was effective August 22, 2006. In the prior year, total revenues for the 2005 third quarter included $2.5 million in development and license revenue for recognition of deferred revenue related to an upfront payment received and approximately $700,000 in reimbursable development costs pursuant to the license agreement entered into with MGI PHARMA.

Total costs and operating expenses for the 2006 third quarter were $11.9 million compared with $11.1 million for the same prior year period. The primary reason for the increase in total costs and operating expenses for the 2006 third quarter was higher research and development costs related to increased product development activities resulting from the acquisition of Montigen Pharmaceuticals earlier this year, inclusion of non-cash charges for the estimated fair value of employee stock options due to the adoption of SFAS 123R on January 1, 2006, severance and retention costs being accrued over the transition service period and higher legal expenses offset by lower sales and marketing expenses resulting from the sale of the Company's North American rights for Nipent and Surface Safe to Mayne Pharma.

The Company reported a net loss for the 2006 third quarter of $2.3 million, or $0.04 per share, compared with a net loss of $2.1 million, or $0.04 per share, for the same prior year period. Included in the net loss for the 2006 third quarter is $565,000 of accrued severance and retention costs, a non-cash charge of $1.1 million for the fair value of employee stock options due to the adoption of SFAS 123R on January 1, 2006 and an income tax provision of $217,000 resulting primarily from the tax effect of the net proceeds received on the sale of the Company's North American rights for Nipent and Surface Safe to Mayne Pharma offset by reimbursed services provided to Mayne Pharma of $658,000, a non-cash gain for a change in valuation of derivatives of $654,000 and a milestone payment earned.

The Company has deferred the entire net gain on the sale of the North American rights for Nipent and Surface Safe to Mayne Pharma that was effective August 22, 2006. The deferred net gain and related contingencies, which are estimated at $12.2 million, are included on the balance sheet and classified as a deferred gain on sale of products to Mayne Pharma. The deferral of the gain is primarily due to a price protection contingency that is currently not estimable. The Company will determine the actual amount to be recognized once the price protection contingency is determined or can be reasonably estimated.

During the 2006 third quarter the Company identified an unrecorded payroll liability involving a U.S. national who formerly worked with the Company in the United Kingdom. The payroll liability relates to personal income tax, penalties and interest and is currently estimated to be an aggregate of approximately $930,000 as of September 30, 2006. The liability originated during the years 2002 through 2006. The Company adopted the provisions of Staff Accounting Bulletin No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements" ("SAB 108") when considering the financial statement treatment and required disclosure for the unrecorded payroll liability. Based on the adoption of SAB 108 the Company determined that $795,000 of the total payroll liability relates to periods prior to 2006 and is included as an adjustment to the accumulated deficit as of January 1, 2006 while the remaining $135,000 of the payroll liability originated during 2006 is included as an adjustment in selling, general and administrative expense for the three and nine-month periods ended September 30, 2006. The cumulative effect of both adjustments, or $930,000, is included as an increase to the Company's accrued payroll and employee benefits liability. Based on the evaluation of the Company's disclosure controls and procedures, as of the quarter and nine months ended September 30, 2006, management has concluded that the Company's disclosure controls and procedures were not effective as of September 30, 2006 because of a material weakness in our internal control over financial reporting. The Company is in the process of remediating this material weakness and is taking appropriate measures to establish additional policies and procedures to ensure that any similar obligations are properly identified and recorded.

Total revenues for the nine months ended September 30, 2006 were $35.2 million compared with $21.0 million for the same prior year period. Total revenues for the nine months ended September 30, 2006, reflects $25.0 million of milestone payments included in development and license revenue and $1.0 million of royalty revenue pursuant to the license agreement entered into with MGI PHARMA during 2004. Net product revenue for the nine months ended September 30, 2006, included Nipent sales of approximately $8.0 million, compared with $9.4 million for the same prior year period. In the prior year, total revenues for the nine months ended September 30, 2005, included $7.4 million in development and license revenue for recognition of deferred revenue related to an upfront payment received and approximately $2.7 million in reimbursable development costs pursuant to the license agreement entered into with MGI PHARMA.

Total costs and operating expenses for the nine months ended September 30, 2006, were $49.0 million compared with $33.5 million for the same prior year period. The primary reason for the increase in total costs and operating expenses for the nine months ended September 30, 2006, was the inclusion of acquired in-process research and development expenses, higher research and development costs related to increased product development activities resulting from the acquisition of Montigen Pharmaceuticals earlier this year, inclusion of non-cash charges for the estimated fair value of employee stock options due to the adoption of SFAS 123R on January 1, 2006, severance and retention costs being accrued over the transition service period and higher legal expenses offset by lower sales and marketing expenses resulting from the sale of the Company's North American rights for Nipent and Surface Safe to Mayne Pharma.

The Company reported a net loss for the nine months ended September 30, 2006 of $10.2 million, or $0.19 per share, compared with a net loss of $10.9 million, or $0.21 per share, for the same prior year period. Included in the net loss for the nine months ended September 30, 2006 is $565,000 of accrued severance and retention costs, a non-cash charge of $2.5 million to operating expenses for the fair value of employee stock options due to the adoption of SFAS 123R on January 1, 2006 and an income tax provision of $252,000 resulting primarily from the tax effect of the net proceeds received on the sale of the Company's North American rights for Nipent and Surface Safe to Mayne Pharma offset by reimbursed services provided to Mayne Pharma of $658,000, a gain of $780,000 representing the difference between the carrying value of a Company equity investment and the proceeds received from the exercise of outstanding warrants issued to certain previous note holders of the convertible debt instruments executed during 2003 to purchase shares of AVI BioPharma Inc.'s common stock at an exercise price of $5.00 per share, a non-cash gain for a change in valuation of derivatives of $1.3 million and milestones payments earned.

The Company's unrestricted cash, cash equivalents and marketable securities increased to $73.2 million at September 30, 2006 compared with $50.7 million from the end of the prior quarter.

Recent Corporate Events:

July 2006: SuperGen announced the achievement of a milestone as a result of the sub-licensing of Dacogen by MGI PHARMA to Cilag GmbH, a Johnson & Johnson company, granting exclusive development and commercialization rights in all territories outside North America. During July 2006, SuperGen received 50% of the $10 million upfront payment and, as a result of both the original agreement with MGI PHARMA and this sublicense with Cilag GmbH, expects to receive up to $23.75 million in future milestone payments as they are achieved for Dacogen globally. Additionally, SuperGen will receive 20% to 30% royalty on all sales worldwide.

August 2006: The Company announced the closing of the sale of SuperGen's North American rights for Nipent and Surface Safe to Mayne Pharma that was effective August 22, 2006.

October 2006: SuperGen announced that its Chief Operating Officer Edward Jacobs will leave the company at year-end following the substantial completion of transition activities related to the sale of SuperGen's North American rights to Nipent and Surface Safe to Mayne Pharma.

BULLETIN! BULLETIN! BULLETIN!
SuperGen will hold a telephone conference call today, Thursday, November 9, 2006, at 9:00 a.m. (EST) / 6:00 a.m. (PST). Dr. James Manuso, Chairman, President and Chief Executive Officer; Edward Jacobs, Chief Operating Officer; and Michael Molkentin, Chief Financial Officer, will discuss the company's performance and answer questions relating to this news release. Those wishing to participate in the call should dial 866-700-7173 (international callers dial 617-213-8838) at approximately 8:50 a.m. (EST). The passcode for the call is 62335620. Those not wishing to participate may listen to the live Webcast of the conference call by visiting http://www.supergen.com. Upon conclusion, an audio recording of the call will be available on SuperGen's Web site for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding SuperGen's obligations to make contingent payments in connection with the acquisition of Montigen, SuperGen's estimation of the amount of the unrecorded payroll tax liability, whether SuperGen will satisfactorily achieve the remaining contingencies surrounding the Mayne Pharma transaction and when or whether the deferred revenue is recognized for accounting purposes and SuperGen's expectation of future milestone payments and royalties on worldwide Dacogen sales. Important factors that could cause actual results to differ materially from the expectations reflected in the forward-looking statements include, but are not limited to, risks and uncertainties related to the achievement of developmental milestones with respect to the compounds acquired in the Montigen acquisition, the actual amount of the payroll liability and its impact on our financial statements, and the ability of MGI to generate global sales of Dacogen. In general, our future success is dependent upon numerous factors, including our ability to generate pre-clinical development candidates for selection into clinical testing, obtaining regulatory approval of Orathecin, conducting and completing clinical trials and obtaining regulatory approval of our other products and product candidates, and creating opportunities for future commercialization of compounds. Our future revenue and operating and net income or loss could be worse than anticipated if demand for our products is less than expected, or if the introduction of new products is delayed, for any reason, including regulatory delay. References made to the discussion of risk factors are detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

SuperGen Noonan Russo
Timothy L. Enns Sharon Weinstein, [phone] (Investors)
S.V.P., Corporate [e-mail]
Communications &
Business Development
[phone] x111 Tracey Milani, [phone] (Media)
[e-mail] [e-mail]


Condensed Consolidated Statements of Operations and Balance Sheets to follow.



SUPERGEN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

Three months ended Nine Months Ended
September 30, September 30,
2006 2005 2006 2005
Revenues:
Net product revenue $2,228 $5,457 $9,096 $10,096
Development and license revenue
from MGI PHARMA, Inc 5,064 3,168 25,064 10,110
Royalty revenue 1,043 - 1,043 -
Distribution agreement and other
revenue - - - 757

Total revenues 8,335 8,625 35,203 20,963

Costs and operating expenses:
Cost of product revenue 482 736 1,877 1,736
Research and development 4,651 3,571 11,509 11,585
Selling, general, and administrative 6,753 6,761 19,312 20,159
Acquired in-process research and
development - - 16,318 -

Total costs and operating
expenses 11,886 11,068 49,016 33,480

Loss from operations (3,551) (2,443) (13,813) (12,517)


Interest income 796 444 1,794 1,227
Gain on disposition of investment in
AVI BioPharma stock resulting from
exercise of warrant - - 780 -
Change in valuation of derivatives 654 (79) 1,327 421

Loss before income tax (2,101) (2,078) (9,912) (10,869)

Income tax provision (217) - (252) -

Net loss $(2,318) $(2,078) $(10,164) $(10,869)
Basic and diluted net loss per
common share $(0.04) $(0.04) $(0.19) $(0.21)
Weighted average shares used in
basic and diluted net loss per
common share calculation 53,607 51,320 52,858 51,215



SUPERGEN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)

September 30, December 31,
2006 2005
(Unaudited)
ASSETS

Current assets:
Cash and cash equivalents $72,974 $47,664
Accounts receivable, net 1,267 5,576
Development revenue receivable
from MGI PHARMA, Inc 64 550
Accounts receivable, Mayne Pharma 658 -
Inventories 168 1,439
Prepaid distribution and marketing rights 1,260 -
Prepaid expenses and other current assets 1,589 1,407
Total current assets 77,980 56,636

Marketable securities, non-current 199 147
Investment in stock of related parties 682 673
Due from related parties, non-current 40 52
Property, plant and equipment, net 3,090 2,907
Goodwill 731 731
Other intangibles, net 1,064 290
Restricted cash and investments, non-current 11,085 11,805
Other assets 20 30
Total assets $94,891 $73,271



LIABILITIES & STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued liabilities $3,477 $3,391
Derivative liability 490 1,817
Payable to AVI BioPharma, Inc. 565 565
Deferred gain on sale of
products to Mayne Pharma 12,235 -
Deferred revenue 1,007 -
Accrued payroll and employee benefits 3,797 2,269
Total current liabilities 21,571 8,042

Deferred rent 952 972
Total liabilities 22,523 9,014

Stockholders' equity 72,368 64,257
Total liabilities and stockholders'
equity $94,891 $73,271


SOURCE SuperGen Inc. 11/09/2006


Web site: http://www.supergen.com
(SUPG)


1974 11/09/2006 08:00 EST http://www.prnewswire.com


"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding SuperGen's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.


Copyright © Supergen



Investors > News Releases

[asics01]

Mayne Pharma Acquires Remaining Nipent(R) Rights
MELBOURNE, Australia, and DUBLIN, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Mayne Pharma Ltd. (ASX: MYP) and SuperGen Inc. (Nasdaq: SUPG) announced today that Mayne has agreed to acquire the remaining worldwide rights to Nipent(R) (pentostatin for injection) for a total consideration of US $8 million.

SuperGen will receive approximately US $3.75 million upfront when the transaction closes. The balance of the purchase price includes US $1.25 million of payments contingent on key events and the remaining US $3 million is payable over a five-year period on the anniversary of the closing date. The transaction is subject to customary closing conditions and regulatory approval.

Nipent(R) is approved for patients with hairy-cell leukaemia. Sales of Nipent(R) in Europe last year were almost US $5 million with France, Germany, Greece, Italy and UK being the key markets. In August 2006 Mayne Pharma acquired the North American rights to Nipent(R) from SuperGen, for a total consideration of US $34 million.

Commenting on today's announcement, Mayne Pharma's Head of Commercial Operations for Europe Middle-East and Africa, Mike Kotsanis, said, "This acquisition is in-keeping with our strategy, announced last May, to acquire niche marketed or close-to-market proprietary products that strengthen our oncology focus across Europe and raise Mayne Pharma's profile with key customers and opinion leaders."

"The transaction marks the completion of SuperGen's transition to a targeted drug discovery and development company that is powered by a strong balance sheet and a well-fuelled royalty and milestone financial engine," said Dr. James S. Manuso, SuperGen's chairman, president and chief executive officer. "The transition of the Nipent(R) North American franchise to Mayne Pharma was very efficient. We expect the same with respect to transitioning this remaining franchise."

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

About Mayne Pharma

Mayne Pharma Ltd. is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than A$800 million in its financial year ended June 30, 2006, and is listed on the Australian Stock Exchange under the symbol 'MYP.' For more information about Mayne Pharma, please visit http://www.maynepharma.com.

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding SuperGen's estimate of its potential tax liability. Important factors that could cause the potential tax liability to be higher or lower include, but are not limited to, the final determination of the potential liability which is currently being assessed. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K and Form 10-Q. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.


Contacts:


Mayne Pharma
Andrew Rowe
Vice President Investor Relations
Mob: [phone]


Teresa La Thangue
Media Relations Manager
Mob: + 44 7920 598 352


Sue Cato
Cato Counsel
Mob: + 61 419 282 319


Matt Horan
Cato Counsel
Mob: + 61 403 934 958


SuperGen/EuroGen
Timothy L. Enns
S.V.P., Corporate Communications & Business Development
Ph: [phone] x 111
Email: [e-mail]


Noonan Russo
Sharon Weinstein
Ph: [phone] (Investors)
Email: [e-mail]


Tracey Milani
Ph: [phone] (Media)
Email: [e-mail]


SOURCE SuperGen Inc. 11/27/2006


Web site: http://www.supergen.com
http://www.maynepharma.com
(SUPG)


5933 11/27/2006 08:00 EST http://www.prnewswire.com


"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding SuperGen's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.


Copyright © Supergen



Investors > News Releases

[asics01]

was gibt es neues ???für supg hohes volumen die letzten tage.will da wer einsteigen oder was geht???
asics

[Taketwo]

Was für eine Achterbahnfahrt! Ich hoffe, jetzt geht es weiter nach Norden! Gibt es News? Wenn ja, bitte posten!

[asics01]

SuperGen dran bleiben


Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von SuperGen (ISIN US8680591067/ WKN 906575) dranzubleiben und bei Bedarf nachzukaufen.

In Analystenkreisen werde dem Krebsforscher Kursvervierfachungspotenzial zugetraut. Seit der Empfehlung im Juli letzten Jahres liege der Titel mit 70% im Plus. Doch es gehe noch um viel mehr. Denn die Technologieplattform des Unternehmens ziele darauf ab, Wirkstoffe zu formulieren, die gezielt die Schutzmechanismen von Krebszellen unterlaufen würden und somit deren Resistenzenausbildung gegenüber Chemotherapie verhindern würden.

Zwar sehe die Pipeline an Präparaten in der klinischen Forschung mit zwei Wirkstoffen nicht überwältigend aus, doch dürften allein schon die derzeit in der Entwicklung stehenden Wirkstoffe MP-470 und MP-529 als extrem spannend gelten. Zudem würden sich die Analysten von Rodman & Renshaw begeistert von der Leistungsfähigkeit der Entwicklungsplattform zeigen, die es dem Unternehmen erlaube, neue Wirkstoffe von der Identifizierung des Drug Targets binnen maximal zwei Jahren in klinische Tests überzuführen.

Aufgrund dieser Leistungsfähigkeit und Schnelligkeit in der Produktentwicklung könnte sich das Unternehmen in den nächsten Jahren ein fast einzigartiges Präparatportfolio in der Krebstherapie aufbauen und zu einem gefragten Partner für große Pharmakonzerne avancieren.

Die Experten von "Global Biotech Investing" raten bei der SuperGen-Aktie dranzubleiben und bei Bedarf nachzukaufen. (Ausgabe 06 vom 26.03.2007) (27.03.2007/ac/a/a)
Analyse-Datum: 27.03.2007

[asics01]

könnte es sein dass MGI PHARMA oder MAYNE PHARMA sich SUPERGEN einverleiben möchten??

[asics01]

Antwort auf Beitrag Nr.: 28.545.295 von asics01 am 28.03.07 16:29:40

warum kein wort über deren ORATHECIN ???

[Taketwo]

HILFE!!!! Was geht denn hier ab??? Steht eine Übernahme bevor????

[asics01]

Antwort auf Beitrag Nr.: 28.638.082 von Taketwo am 03.04.07 13:22:28

ich trade supg schon lange aber der kursverlauf der letzten wochen lässt doch schwer vermuten dass irgendwo was am kochen ist.doch was übernahme,news,?????

[asics01]

Nipent(R) Acquisition by Hospira is Complete

DUBLIN, Calif., April 3 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG) today announced that it closed on the sale of the remaining worldwide rights for Nipent(R) (pentostatin for injection) to Mayne Pharma, which was acquired in February 2007 by Hospira, for a total consideration of US$8 million. SuperGen received an initial up-front payment of US$3.75 million as a condition of the closing.

The balance of the purchase price is guaranteed and payable over a five- year period on the anniversary of the closing date, except for US$1.25 million that SuperGen will receive when contractual conditions are met.

This transaction complements the previously reported sale of the North American rights to Mayne Pharma. Both transactions taken together complete our sale of all rights to Nipent. Total consideration from both transactions could total US$42 million.

Nipent(R) is approved for patients with hairy-cell leukaemia.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to conclude negotiations on the sale of Nipent, the achievement of royalties or milestones from the Dacogen licensure, and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakes no duty to update any of these forward- looking statements to conform them to actual results.

Contacts:
SuperGen
Timothy L. Enns
S.V.P., Corporate Communications
[phone] x111
[e-mail]

Noonan Russo
Greg Geissman
Director of Media Relations & Business Development
858-646-3058
[e-mail]

SOURCE SuperGen Inc.
-0- 04/03/2007
/CONTACT: Timothy L. Enns S.V.P., Corporate Communications of SuperGen,
[phone] x111, or [e-mail]; or Greg Geissman, Director of
Media Relations & Business Development of Noonan Russo, [phone], or
[e-mail] /
/Web site: http://www.supergen.com /
(SUPG)

CO: SuperGen Inc.; Hospira
ST: California, New York
IN: MTC HEA
SU: TNM

CL-AA
-- CLTU085 --
7039 04/03/2007 08:00 EDT http://www.prnewswire.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding SuperGen's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.
Copyright © Supergen

[asics01]

Antwort auf Beitrag Nr.: 28.645.002 von asics01 am 03.04.07 18:11:19

diese meldung kann aber nicht der grund allein sein für den anstieg der letztzen tage.oder doch???

[Riddim_mann]

Es gab eine Kaufempfelung vom Aktionär mit einem sehr konservativen KZ von 6,50.

Sie schreiben das Supergen ein möglicher Übernahme Kandidat sei und Rodman & Renshaw sogar ein KZ von 24 US$ angibt. das Wären über 250% beim jetzigen Kurs....

[Taketwo]

Wow, die Aktie geht zur Zeit nur UP!!!! Stetig nach Norden!!! Und hier merkt das keiner!!! Bin schon satt im Plus!!!

[Riddim_mann]

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
Other Presentations at AACR Highlight Progress in SuperGen's Oncology-Focused Pre-Clinical Pipeline
LOS ANGELES, April 19 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG) today announced that MP470, its multi-targeted tyrosine kinase inhibitor, suppresses the Rad51 protein, a critical component of double- stranded DNA repair in cancer cells as part of a series of presentations at the 2007 American Association for Cancer Research Annual Meeting (Abstract 4028).

Additional research findings presented by SuperGen scientists and their collaborators included data pertaining to the improved bioavailability and tolerability of the hydrochloride salt of MP470 as compared to the free base (Abstract 1540). Two posters also demonstrated the use of SuperGen's proprietary CLIMB technology and drug discovery process to facilitate lead development and the design of several novel small molecule inhibitors, including Axl kinase (Abstract 2380), as well as inhibitors of Jak2 (Abstract 2387).

The company also presented new animal model studies for small molecule inhibitors of DNMT1 in zebrafish (Abstract 2229), data from its preclinical compound MP529, a selective Aurora A kinase inhibitor (Abstract 3261) and new data exhibiting receptor tyrosine kinase inhibition in combination with an inhibitor of EGFR in mouse xenograft models (Abstract 5421). Finally, a mini- symposium was presented about work conducted at The Ohio State University on SuperGen's novel DNA hypomethylating agents that selectively induced degradation of DNMT1 in human cancer cells (Abstract 4142).

Copies of the poster presentations will be available in the pipeline section of SuperGen's Web site www.supergen.com.

"We are very encouraged by the strength of the preclinical data from our drug discovery and development programs and are awaiting the initiation of the Phase 1 clinical trial of MP470," said Dr. James S. Manuso, SuperGen's Chairman, President and Chief Executive Officer. "Our products and programs were highlighted in seven posters and a mini-symposium. The data presented brings to light important new aspects of our late-stage preclinical compounds and also validates CLIMB as a rapid and powerful process for the identification of a broad range of potent small molecule inhibitors."

Abstract No. 4028

MP470, a potent suppressor of Rad51, improves response to platinum-based anticancer agents

Rad51 is an important protein involved in resistance to cytotoxic/DNA damaging therapies that are commonly used to treat tumors. It acts to repair the double stranded DNA breaks that are caused by therapies, thus limiting their efficacy and increasing dosage requirements. Data indicate that SuperGen's novel compound, MP470, blocks the induction of Rad51 by anticancer platinum agents. MP470, in combination with carboplatin and paclitaxel in small cell and non-small cell lung cancer lines, showed a significant improvement in tumor response over the carboplatin/paclitaxel treatments alone. A combination therapy regimen that includes MP470 in addition to a platinum-based cytotoxic agent could reduce dosage requirements and widen the therapeutic window.

Abstract No. 1540

Hydrochloride salt of MP470, a potent suppressor of Rad51, improves bioavailability and tolerability

Results from this study suggest that the hydrochloride salt of MP470 (MP470.HCl) could lead to improved safety and tolerability of the compound. Data indicate that MP470.HCl exhibits a several-fold improvement in oral bioavailability when compared to the free base. The compound had a wide therapeutic window in rat and dog models. Additionally, no apparent serious toxicities in the expected therapeutic dose range were observed.

Abstract No. 2380

Discovery and characterization of a series of Axl kinase inhibitors using the CLIMB process

Using CLIMB, researchers created a model of Axl kinase to screen a large virtual library of chemical structures from which five chemical lead scaffolds were selected. Structural modifications improved biochemical and cell-based potency that resulted in compounds that exhibit sensitization to apoptosis and down regulation of Axl-dependent signaling pathways. Inhibitor SGI-AXL-277, a pyrrolopyrimidine, demonstrated low micromolar activity against the Axl enzyme and in cell proliferation assays. Lead optimization toward the identification of a clinical candidate is ongoing.

Abstract No. 2387

Discovery and characterization of small molecule inhibitors for Jak2

Janus kinases (JAKs) are critical to a number of intracellular signaling pathways. Failure of Jak2 regulation or mutations that activate Jak2 expression are implicated in leukemias, lymphomas and various solid tumors. Utilizing CLIMB, researchers used a Jak2 crystal structure to build several models that were made into a substrate for screening a large, virtual small molecule library. This process generated a subset of leads based on calculated binding energies. These leads were then screened in silico to determine "druggable" candidates. Cell-based activity was determined in HEL, K562, MO7 and other human cancer cell lines.

Abstract No. 2229

Zebrafish as a model mechanistic screen for small molecule inhibitors of DNMT1

Data suggest that the zebrafish model offers a fast and reliable method to identify small molecule inhibitors of DNA methyltransferase (DNMT). DNMT1 is considered to be the DNA methyltransferase enzyme mainly responsible for maintaining abnormal promoter methylation in various cancer types. Zebrafish embryos are a viable model for cancer drug research because of their close similarity to humans and their fast and easily visible development. Small molecules that inhibit DNMT1 should produce terminal differentiation abnormalities of the gut tube, retina and exocrine pancreas, all of which are easily visualized. This screen allows quick validation of DNMT1 inhibition in vivo, as well as important data on the toxicity of compounds tested.

Abstract No. 3261

Discovery and development of MP529, a new effective and selective inhibitor of Aurora A kinase

MP529 series compounds, such as SGI-498, SGI-503, SGI-1097 and SGI-1215, demonstrate potent nanomolar inhibitory activity against the Aurora-A enzyme in biochemical enzyme-based assays, while exhibiting little to no activity versus the Aurora B kinase. SuperGen developed this series of lead compounds for use in anticancer therapy using rational-based drug design. Extensive in silico screening reduced the number of compounds submitted to physical assays to fewer than 100, saving significant time and resources over standard drug discovery practices. The series of compounds was evaluated in in vivo xenograft models and showed efficacy while maintaining desirable pharmacokinetic properties.

Abstract No. 5421

Dual inhibition of receptor tyrosine kinases of PDGFR and EGFR abolishes prostate cancer cell growth in culture and in a mouse xenograft model by complete dephosphorylation of PKB/Akt

MP470, SuperGen's multi-targeted tyrosine kinase inhibitor, in combination with Tarceva was more effective than either treatment alone in the inhibition of cell proliferation and phosphorylation of Akt in EGF and PDGF pathways. Moreover, in combination with Tarceva, MP470 inhibited Akt phosphorylation in LNCaP prostate cells. Finally, the MP470/Tarceva treatment was shown to abolish prostate tumor growth in an LNCaP xenograft mouse model

Mini-symposium Abstract No. 4142

Novel DNA hypomethylating agents: non-nucleoside compounds that do not incorporate into DNA selectively induce degradation of DNA methyltransferase I (DNMT1) in human cancer cells by the proteasomal pathway and re-express silenced tumor suppressor genes

Researchers have discovered a novel class of quinoline-based compounds that are not incorporated into DNA and cause selective degradation of DNMT1 in human cancer cells with minimal or no effects on DNMT3A and DNMT3B that have been discovered. This addresses an issue with re-activation of silenced tumor suppressor genes by 5-Azacytidine (5-AzaC or Vidaza) and its congener 5-aza- deoxycydinite (5-aza-CdR or Decitabine or Dacogen). These compounds provide a different mechanistic approach to the creation of cancer therapies because they selectively and rapidly induce degradation of maintenance DNA methyltransferase, DMNT1. However, they show some toxicity due to their incorporation into the cell DNA. One compound in particular, S1027, resulted in complete degradation of DNMT1 within 24 hours of treatments and also blocked degradation as a pre-treatment of cells with proteasomal inhibitors.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit http://www.supergen.com.

This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. The actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These forward-looking statements include statements regarding the ability of our products to enter clinical trials and the potential validation of our discovery process to produce new compounds. SuperGen's products may not enter clinical trials and even if these products do enter clinical testing there is no assurance that these tests will be successful. Additionally, the early successes in preclinical work may not be a validation of our discovery process and past success may not predict future success. Other factors that could cause actual results to differ materially from expectations include, but are not limited to, the risk factors detailed in the Company's filings with the Securities and Exchange Commission including reports on its most recently filed Form 10-K. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.


Contacts:
SuperGen Noonan Russo
Timothy L. Enns Greg Geissman
S.V.P., Corporate Communications Director of Media Relations
& Business Development
[phone] x111 [phone]
[e-mail] [e-mail]


SOURCE SuperGen Inc.
04/19/2007

[Riddim_mann]

wolltmal nachfragen ob einer von euch weiß wann die Jahreszahlen kommen sollen??

Sind schon irgendwelche Ergebnisse der Phase 3 von Orathecin.

Wäresehr dankar bin nämlich am überlegen ob ich einsteigen soll oder eher noch etwas warten sollte

[asics01]

SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470
First-in-Human Study Triggers Stock Milestone Payment
DUBLIN, Calif., April 25 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG - News) today announced that the Food and Drug Administration cleared MP470, a novel oral multi-targeted tyrosine kinase inhibitor (TKI), for a first-in-human Phase I clinical trial. ADVERTISEMENT

The Phase I accelerated titration dose-escalation trial will assess the safety and tolerability of MP470 and determine the maximum tolerated dose (MTD). Pharmacokinetic and biomarkers data will also be collected and assessed to assist in designing follow-on clinical studies for the use of MP470 as a single agent and in combination treatment modalities. Up to 30 patients with advanced stage solid tumor cancers will be enrolled.

"Today signifies our complete transition to a discovery and development company." said Dr. James S. Manuso, SuperGen's Chairman, President and Chief Executive Officer. "Strategically, we remain focused on becoming a key player in the hematology and oncology markets. Not only will we enter the clinic with MP470 this quarter, we anticipate advancing MP529, our selective Aurora-A kinase inhibitor, into clinical trials later this year."

The Phase I study protocol is undergoing final approval by Institutional Review Boards at two study centers in the U.S. The first patient is expected to be treated later this quarter.

The receipt of FDA clearance for the MP470 first-in-human use triggers a milestone payment to the previous Montigen shareholders of $10 million dollars to be paid in SuperGen common stock.

About MP470

MP470 is an oral selective multi-targeted TKI that inhibits MET, RET and the mutant forms of KIT, PDGFR and FLT3 as well as suppresses the Rad51 protein, a critical component of double-stranded DNA repair in cancer cells. The compound was developed using a fragment-based approach with the aid of company's CLIMB(TM) technology.

About SuperGen

Based in Dublin, Calif., SuperGen is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, whether and when the first patients will be enrolled in the trial, the overall success of the Phase I trial protocol for MP470 and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission, including its most recently filed Form 10- K. SuperGen Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.



Contacts:
SuperGen Noonan Russo
Timothy L. Enns Greg Geissman
S.V.P., Corporate Director of Media Relations
Communications & Business
Development [phone]
[phone] x111 [e-mail]
[e-mail]



Source: SuperGen Inc.

[asics01]

was ist denn mit ORATHECIN los???in deren pipline nicht mehr geführt

[megachance]

Antwort auf Beitrag Nr.: 29.016.592 von asics01 am 26.04.07 16:34:17

Hallo asics01,

nein, habe ich auch nicht mehr auf der Homepage bei der Entwicklungsübersicht gesehen. Im Aktionär 15/07 war Oracethin aber noch erwähnt als sehr aussichtsreich, da es sich ja schon in der dritten Phase der klinischen Studien befand... Hast du inzwischen mehr herausgefunden?
Überhaupt schade, dass so eine Aktie, die meiner Meinung gutes Potential hat aufgrund der Vielfältigkeit auch in der Diskussion nicht mehr "Anhänger" findet...
Viele Grüße
Megachance

[meinBrot]

Hier eigentlich noch wer drin?

Kursziel 18$ - haha...

[asics01]

wer ist denn noch an board???oder haben alle das sinkende schiff verlassen

[asics01]

werden die gerade sturmreif geschossen??

asics